What's in Korea United Pharm. Inc.'s pipeline?

Korea United Pharm. Inc. has 19 drugs in our index: 2 marketed, 0 filed, 3 in Phase 3, 1 in Phase 2, 13 in Phase 1.

Which companies overlap with Korea United Pharm. Inc.'s portfolio?

Top competitors by shared drug class: Merck Sharp & Dohme LLC, Abbott, University of Chicago, AJU Pharm Co., Ltd., AceLink Therapeutics, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/korea-united-pharm-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Korea United Pharm. Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Korea United Pharm. Inc. pipeline: 2 marketed, 0 filed, 3 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 3 Phase 3 1 Phase 2 13 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Cefecin Tab.	Cefecin Tab.	marketed
Omnicef Cap.	Omnicef Cap.	marketed	Third-generation cephalosporin	Penicillin-binding proteins (PBPs)	Infectious Disease
KALOMIN™ Tab.	KALOMIN™ Tab.	phase 3	Potassium supplement / Electrolyte replacement	Potassium ion (K+)	Electrolyte/Metabolic Disorders
Umckamin syrup	Umckamin syrup	phase 3	Herbal immunomodulator		Respiratory / Immunology
UI05MSP015CT	UI05MSP015CT	phase 3	SGLT2 inhibitor	SGLT2	Diabetes

Therapeutic area mix

Diabetes · 1
Electrolyte/Metabolic Disorders · 1
Infectious Disease · 1
Other · 1
Respiratory / Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Merck Sharp & Dohme LLC · 2 shared drug classes
Abbott · 2 shared drug classes
University of Chicago · 2 shared drug classes
AJU Pharm Co., Ltd. · 1 shared drug class
AceLink Therapeutics, Inc. · 1 shared drug class
Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
Aciex Therapeutics, Inc. · 1 shared drug class
AO GENERIUM · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Korea United Pharm. Inc.:

Cite this brief

Drug Landscape (2026). Korea United Pharm. Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/korea-united-pharm-inc. Accessed 2026-05-16.